Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of YK-029A versus platinum-doublet chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated advanced or metastatic non-small cell lung cancer
CTR20230490Phase 3Active
- Sponsor
- Hainan Yuekang Biological Medicine
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pruvonertinib in non-small cell lung cancer (NSCLC), sponsored by Hainan Yuekang Biological Medicine. Started Apr 2023; status: active.
02
Drugs
pruvonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20230490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230490.